SEARCH:
Print

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, May 29, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 

1.

Details of the   person discharging managerial responsibilities/person closely associated  

a)

Name

Paul Chaplin

2.

Reason for the   notification

a)

Position/status

 

President and Chief Executive Officer of Bavarian   Nordic A/S

b)

Initial notification/Amendment

Initial notification

3.

Details of the   issuer, emission allowance market participant, auction platform, auctioneer   or auction monitor

a)

Name

Bavarian Nordic A/S

b)

LEI

2138006JCDVYIN6INP51

4.

Details of the transaction(s):   section to be repeated for (i) each type of instrument; (ii) each type of   transaction; (iii) each date; and (iv) each place where transactions have   been conducted

a)

Description of   the financial instrument, type of instrument
 
 

Identification   code

Shares


 
  DK0015998017

b)

Nature of the   transaction

Sale

c)

Price(s) and   volume(s)

Price(s)

Volume(s)

 

 

DKK 198.80

DKK 198.90

DKK 199.00
  DKK 199.10

DKK 199.30
  DKK 199.50

DKK 199.55

DKK 199.70

DKK 199.80

DKK 199.90

DKK 200.00
  DKK 200.05

DKK 200.10

DKK 200.20

DKK 200.40

DKK 200.60

DKK 200.80

DKK 200.90

DKK 201.00

DKK 201.10

DKK 202.20

DKK 201.30

DKK 201.40

DKK 201.50

DKK 201.60

DKK 201.70

DKK 201.80

DKK 201.90

DKK 202.00

DKK 202.20

DKK 202.40

DKK 202.60

DKK 202.80

DKK 203.00

DKK 203.20

54
  43

58

1,430
  75
  312

109

17

958

1,111

1,811

82
  159

7,171

2,002

1,682

1,942

231

5,401

196

2,816

153

2,315

563

3,091

345

2,462

486

3,798

810

909

1,186

835

3,487

2,702

d)

Aggregated information

-           Aggregated   volume

-           Price

 

50,802

DKK 10,223,659.20

e)

Date of the   transaction

2020-05-29

f)

Place of the   transaction

Nasdaq Copenhagen A/S, XCSE

 

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains market-leading vaccines Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit www.bavarian-nordic.com.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 

Company Announcement no. 34 / 2020

Published on May 29, 2020, 20:00 CET